Upsher-Smith Launches Propafenone Hydrochloride Extended-Release Capsules

Jul. 02. 2020

Maple Grove, MN - June 30, 2020 - Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) announced the launch of Propafenone Hydrochloride Extended-Release Capsules in 225 mg, 325 mg and 425 mg strengths (the branded product: RYTHMOL® SR). The product was approved by the U.S. Food and Drug Administration (FDA).

Propafenone Hydrochloride Extended-Release Capsules 225 mg, 325 mg and 425 mg are prescribed for use in prolonging time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic AF without structural heart disease.

The propafenone hydrochloride extended-release capsule market had U.S. sales of approximately $51 million for the 12 months ending May 2020 according to IQVIA.

*RYTHMOTH SR is a trademark owned by or licensed to the GSK group of companies.

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.

As Upsher-Smith begins its second century in business, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit